# 503640212 01/08/2016

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3686845

SUBMISSION TYPE:		NEW ASSIGNMENT			
NATURE OF CONVEYANCE: NUNC PRO TUNC ASSIGNMENT					
EFFECTIVE DATE:		02/27/2013			
CONVEYING PARTY D	ΑΤΑ				
		Name	Execution Date		
CYTOCHROMA INC.			02/27/2013		
RECEIVING PARTY DA	ТА				
Name:	CYTOC	HROMA CAYMAN ISLANDS LTD.			
Street Address:	C/O MA	PLES CORPORATE SERVICES			
Internal Address:	PO BO	K 309, UGLAND HOUSE			
City:	GRAND	CAYMAN			
State/Country:	CAYMA	N ISLANDS			
Postal Code:	KY1-11	04			
Application Number:		14690131			
Property Type Application Number:		Number 14690131			
CORRESPONDENCE D		(312)474-0448			
Fax Number: <i>Correspondence will b</i>	e sent to	(312)474-0448 the e-mail address first; if that is ; if that is unsuccessful, it will be			
Fax Number: <i>Correspondence will b</i>	e sent to provided	( )			
Fax Number: <i>Correspondence will be using a fax number, if p</i> Email: Correspondent Name:	e sent to provided	<i>the e-mail address first; if that is</i> <i>; if that is unsuccessful, it will be</i> anagelberg@marshallip.com MARSHALL, GERSTEIN & BORUN	sent via US Mail.		
Fax Number: <i>Correspondence will be using a fax number, if p</i> Email: Correspondent Name: Address Line 1:	) e sent to provided i i i i i i	<i>the e-mail address first; if that is</i> <i>; if that is unsuccessful, it will be</i> anagelberg@marshallip.com MARSHALL, GERSTEIN & BORUN 233 SOUTH WACKER DRIVE	sent via US Mail.		
Fax Number: <i>Correspondence will be using a fax number, if p</i> Email: Correspondent Name: Address Line 1: Address Line 2:	e sent to provided i i i i i i i i i i i i i i i i i i	<i>the e-mail address first; if that is</i> <i>; if that is unsuccessful, it will be</i> anagelberg@marshallip.com MARSHALL, GERSTEIN & BORUN 233 SOUTH WACKER DRIVE SUITE 6300	sent via US Mail.		
Fax Number: <i>Correspondence will buusing a fax number, if p</i> Email: Correspondent Name: Address Line 1: Address Line 2: Address Line 4:	e sent to brovided	<i>the e-mail address first; if that is ; if that is unsuccessful, it will be</i> anagelberg@marshallip.com MARSHALL, GERSTEIN & BORUN 233 SOUTH WACKER DRIVE SUITE 6300 CHICAGO, ILLINOIS 60606	sent via US Mail.		
Fax Number: <i>Correspondence will be using a fax number, if p</i> Email: Correspondent Name: Address Line 1: Address Line 2: Address Line 4:	e sent to brovided	the e-mail address first; if that is ; if that is unsuccessful, it will be anagelberg@marshallip.com MARSHALL, GERSTEIN & BORUN 233 SOUTH WACKER DRIVE SUITE 6300 CHICAGO, ILLINOIS 60606 31138/43029F	sent via US Mail.		
Fax Number: <i>Correspondence will be using a fax number, if p</i> Email: Correspondent Name: Address Line 1: Address Line 2: Address Line 4: ATTORNEY DOCKET NU	e sent to brovided	the e-mail address first; if that is ; if that is unsuccessful, it will be anagelberg@marshallip.com MARSHALL, GERSTEIN & BORUN 233 SOUTH WACKER DRIVE SUITE 6300 CHICAGO, ILLINOIS 60606 31138/43029F AUDREY NAGELBERG	sent via US Mail.		
Fax Number: <i>Correspondence will be using a fax number, if p</i> Email: Correspondent Name: Address Line 1: Address Line 2: Address Line 4: ATTORNEY DOCKET NUME NAME OF SUBMITTER: SIGNATURE:	e sent to brovided	the e-mail address first; if that isif that is unsuccessful, it will beanagelberg@marshallip.comMARSHALL, GERSTEIN & BORUN233 SOUTH WACKER DRIVESUITE 6300CHICAGO, ILLINOIS 6060631138/43029FAUDREY NAGELBERG/Audrey Nagelberg/	sent via US Mail.		
Fax Number: <i>Correspondence will be using a fax number, if p</i> Email: Correspondent Name: Address Line 1: Address Line 2: Address Line 4: ATTORNEY DOCKET NU	e sent to brovided	the e-mail address first; if that is ; if that is unsuccessful, it will be anagelberg@marshallip.com MARSHALL, GERSTEIN & BORUN 233 SOUTH WACKER DRIVE SUITE 6300 CHICAGO, ILLINOIS 60606 31138/43029F AUDREY NAGELBERG	sent via US Mail.		
Fax Number: Correspondence will be using a fax number, if p Email: Correspondent Name: Address Line 1: Address Line 2: Address Line 2: Address Line 4: ATTORNEY DOCKET NUME NAME OF SUBMITTER: DATE SIGNED: Total Attachments: 26	e sent to provided	the e-mail address first; if that isif that is unsuccessful, it will beanagelberg@marshallip.comMARSHALL, GERSTEIN & BORUN233 SOUTH WACKER DRIVESUITE 6300CHICAGO, ILLINOIS 6060631138/43029FAUDREY NAGELBERG/Audrey Nagelberg/	sent via US Mail.		
Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Email: Correspondent Name: Address Line 1: Address Line 2: Address Line 2: Address Line 4: ATTORNEY DOCKET NUME ATTORNEY DOC	e sent to provided 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	the e-mail address first; if that isif that is unsuccessful, it will beanagelberg@marshallip.comMARSHALL, GERSTEIN & BORUN233 SOUTH WACKER DRIVESUITE 6300CHICAGO, ILLINOIS 6060631138/43029FAUDREY NAGELBERG/Audrey Nagelberg/	sent via US Mail.		
Fax Number: Correspondence will be using a fax number, if p Email: Correspondent Name: Address Line 1: Address Line 2: Address Line 2: Address Line 4: ATTORNEY DOCKET NUME NAME OF SUBMITTER: DATE SIGNED: Total Attachments: 26	e sent to provided	the e-mail address first; if that isif that is unsuccessful, it will beanagelberg@marshallip.comMARSHALL, GERSTEIN & BORUN233 SOUTH WACKER DRIVESUITE 6300CHICAGO, ILLINOIS 6060631138/43029FAUDREY NAGELBERG/Audrey Nagelberg/	sent via US Mail.		

source=Assignment3#page5.tif source=Assignment3#page6.tif source=Assignment3#page7.tif source=Assignment3#page8.tif source=Assignment3#page9.tif source=Assignment3#page10.tif source=Assignment3#page11.tif source=Assignment3#page12.tif source=Assignment3#page13.tif source=Assignment3#page14.tif source=Assignment3#page15.tif source=Assignment3#page16.tif source=Assignment3#page17.tif source=Assignment3#page18.tif source=Assignment3#page19.tif source=Assignment3#page20.tif source=Assignment3#page21.tif source=Assignment3#page22.tif source=Assignment3#page23.tif source=Assignment3#page24.tif source=Assignment3#page25.tif source=Assignment3#page26.tif

#### ASSIGNMENT AGREEMENT

This assignment agreement ("Assignment") is entered into the  $\partial 7^{+4}$  day of <u>February</u> 2013 ("Effective Date") by and between **Cytochroma Inc.**, a company having a principal place of business at Ontario, Canada ("Assignor") and **Cytochroma Cayman Islands Ltd.**, a company having a principal place of business at c/o Maples Corporate Services, PO Box 309 Ugland House, Grand Cayman, KY1-1104 Cayman Islands ("Assignee").

For good and valuable consideration, the receipt and sufficiency of which are agreed, Assignor hereby irrevocably sells, assigns and transfers to Assignee and its successors, assigns and legal representatives. Assignor's entire right, title and interest, both legal and equitable, throughout the world, in the patents and patent applications listed in the attached Exhibit A, and to the inventions described therein and improvements thereof, all related patent applications throughout the world including those claiming priority thereto anywhere in the world, the right of priority, including without limitation to claim priority benefit of or to said patent applications, all continuations, divisionals and continuations-in-part of any of the foregoing, patents issuing from any of the foregoing, and reissues, reexaminations, extensions and foreign equivalents thereof and supplementary protection certificates allowed on any of the foregoing (collectively the "Patent Rights") for Assignee's own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made; together with all income, royalties, damages or payments due or payable as of the Effective Date or thereafter. including, without limitation, all claims for damages by reason of past, present or future infringement or other unauthorized use of the Patent Rights, with the right to sue for, and collect the same for its own use and enjoyment, and for the use and enjoyment of its successors, assigns, or other legal representatives.

Upon the request of Assignee, the undersigned agrees to execute any and all documents and take actions reasonably requested to effectuate this Assignment and Assignee's rights in the Patent Rights, including any oath or affidavit relating thereto, to cooperate to the best of the ability of the undersigned with Assignee in preparing and executing statements and giving and producing evidence in support of the Patent Rights, and to perform any and all acts reasonably requested by Assignee to obtain, enforce and defend the Patent Rights and vest all rights therein to Assignee as fully and entirely as the same would have been held and enjoyed by the undersigned if this Assignment had not been executed.

The parties execute and deliver this Assignment by their respective signatories below.

Cytochroma Inc.

Cytochroma Cayman Islands Ltd.

Date: February 27, 2013

-

Name: Andrew Dean

Title: Director

Name: Charles Bishop

Title: President and Chief Executive Officer

Date: \_\_\_\_\_, 2013

Witnesses:

Witnesses:

WA WOUDY GOANS

Cytochroma Inc.

Cana Birg

Name: Charles Bishop

Title: President and Chief Executive Officer

Date: February 27, 2013

Witnesses:

Cytochroma Cayman Islands Ltd.

Name: Andrew Dean

Title: Director

Date: \_\_\_\_\_\_ 2013

Witnesses:

## **Exhibit A - Patents**

Application No.	Filed	Country	Issued	Patent No.	Title
2002302253	5/23/2002	Australia			A RETINOIC ACID METABOLIZING CYTOCHROME P450
2448933	5/23/2002	Canada	5/15/2012	2448933	A RETINOIC ACID METABOLIZING CYTOCHROME P450
02729713.4	5/23/2002	European Patent Office			A RETINOIC ACID METABOLIZING CYTOCHROME P450
1974/DELNP	5/23/2002	India			A RETINOIC ACID METABOLIZING CYTOCHROME P450
2002592495	5/23/2002	Japan			A RETINOIC ACID METABOLIZING CYTOCHROME P450
CA02/00758	5/23/2002	PCT		~-	A RETINOIC ACID METABOLIZING CYTOCHROME P450
10/477,526	8/16/2004	United States of America	2/26/2008	7,335,756	RETINOIC ACID METABOLIZING CYTOCHROME P450
60/292,531	5/23/2001	United States of America			A RETINOIC ACID METABOLIZING CYTOCHROME P450
2431640	12/17/2001	Canada		-	P450RAI-2(P450 CYTOCHROME 26B),ENCODING NUCLEIC ACID MOLECULES AND METHODS AND USES THEREOF
10/433,485	11/13/2003	United States of America	10/3/2006	7,115,558	P450RAI-2(P450 CYTOCHROME 26B),ENCODING NUCLEIC ACID MOLECULES AND METHODS AND USES THEREOF
CA01/01805	12/17/2001	PCT		~-	P450RAI-2(P450 CYTOCHROME 26B), ENCODING NUCLEIC ACID MOLECULES AND METHODS AND USES THEREOF
11/498,250	8/3/2006	United States of America	8/25/2009	7,579,329	P450RAI-2 (P450 CYTOCHROME 26B), ENCODING NUCLEIC ACID MOLECULES AND METHODS AND USES THEREOF

3

Application No.	Filed	Country	Issued	Patent No.	Title
12/546,450	8/24/2009	United States of America			P450RAI-2 (P450 CYTOCHROME 26B), ENCODING NUCLEIC ACID MOLECULES AND METHODS AND USES THEREOF
2001250216	4/20/2001	Australia			A THYMUS EXPRESSED HUMAN CYTOCHROME P450(P450TEC)
01923443.4	4/20/2001	European Patent Office	-		A THYMUS EXPRESSED HUMAN CYTOCHROME P450(P450TEC)
2001578656	4/20/2001	Japan			A THYMUS EXPRESSED HUMAN CYTOCHROME P450(P450TEC)
2002010267	4/20/2001	Mexico	<b>4</b>	<b>1</b>	A THYMUS EXPRESSED HUMAN CYTOCHROME P450(P450TEC)
CA01/00547	4/20/2001	PCT			A THYMUS EXPRESSED HUMAN CYTOCHROME P450 (P450TEC)
10/257,378	4/4/2003	United States of America			THYMUS EXPRESSED HUMAN CYTOCHROME P450(P450TEC)
60/198,617	4/20/2000	United States of America			HUMAN CYTOCHROME P450TEC
60/208,785	6/1/2000	United States of America			HUMAN CYTOCHROME P450TEC
2484244	5/2/2003	Canada			STABLE CYTOCHROME P450 24 (CYP24) EXPRESSING CELL LINE AND METHODS AND USES THEREOF
CA03/00620	5/2/2003	PCT			STABLE CYTOCHROME P450 24 (CYP24) EXPRESSING CELL LINE AND METHODS AND USES THEREOF
10/513,302	10/3/2005	United States of America	10/30/2007	7,288,407	STABLE CYTOCHROME P450 24 (CYP24) EXPRESSING CELL LINE AND METHODS AND USES THEREOF
60/376,806	5/2/2002	United States of America			CYP24 STABLE CELL LINE FOR DRUG SCREEING
2494572	12/17/2004	Canada			CYTOCHROME P450 24 (CYP24) MONOCLONAL ANTIBODY AND METHODS AND USES THEREOF

ş

Application No.	Filed	Country	Issued	Patent No.	Title
11/013,435	12/17/2004	United States of America	9/23/2008	7,427,670	CYTOCHROME P450 24 (CYP24) MONOCLONAL ANTIBODY AND METHODS AND USES THEREOF
60/530,604	12/19/2003	United States of America			CYTOCHROME P450 24 (CYP24) MONOCLONAL ANTIBODY AND METHODS AND USES THEREOF
2396511	12/15/2000	Canada		** **	CYTOCHROME P450RAI- 2 AND RELATED PROTEINS
CA00/01493	12/15/2000	РСТ			CYTOCHROME P450RAI- 2 AND RELATED PROTEINS
10/148,883	2/13/2003	United States of America	5/26/2009	7,537,919	Cytochrome P450RA1-2 and related proteins
60/171,110	12/16/1999	United States of America			P450RAI-2 AND RELATED PROTEINS
60/178,314	1/27/2000	United States of America			IDENTIFICATION OF THE HUMAN CYTOCRHOME P450, P450RAI-2 WHICH IS PREDOMINANTLY EXPRESSED IN THE ADULT CEREBELLUM AND IS RESPONSIBLE FOR ALL TRANS RETINOIC ACID METABOLISM
CA02/00163	2/11/2002	PCT			CLONING AND CHARACTERIZATION OF A NOVEL HUMAN CYTOCHROME P450, CYP 27C1, AND A HYBRID HOMOLOG FROM XENOPUS LEAVIS
60/267,410	2/9/2001	United States of America			CLONING AND CHARACTERIZATION OF A NOVEL HUMAN CYTOCHROME P450, CYP 27C1, AND A HYBRID HOMOLOG FROM XENOPUS LEAVIS
60/527,754	12/9/2003	United States of America			1ALPHA,25- DIHYDROXYVITAMIN D3 ANALGOS
60/862,876	10/25/2006	United States of America			COMPOSITIONS AND METHODS FOR TREATING HYPERPHOSPHATEMIA IN HUMANS

Application No.	Filed	Country	Issued	Patent No.	Title
60/913,849	4/25/2007	United States of America			METHOD OF TREATING VITAMIN D INSUFFICIENCY AND DEFICIENCY
2683628	4/25/2008	Canada		**	METHOD OF TREATING VITAMIN D INSUFFICIENCY AND DEFICIENCY
200880013367.X	4/25/2008	China			METHOD OF TREATING VITAMIN D INSUFFICIENCY AND DEFICIENCY
08837933.4	4/25/2008	European Patent Office			METHOD OF TREATING VITAMIN D INSUFFICIENCY AND DEFICIENCY
2010-504912	4/25/2008	Japan			METHOD OF TREATING VITAMIN D INSUFFICIENCY AND DEFICIENCY
10-2009-7024309	4/25/2008	Korea, Republic of			METHOD OF TREATING VITAMIN D INSUFFICIENCY AND DEFICIENCY
<b>B08/003480</b>	4/25/2008	PCT	~ -		METHOD OF TREATING VITAMIN D INSUFFICIENCY AND DEFICIENCY
12/597,230	12/24/2009	United States of America			METHOD OF TREATING VITAMIN D INSUFFICIENCY AND DEFICIENCY
60/940,866	5/30/2007	United States of America			PROCESS FOR PRODUCING PHOSPHINEOXIDE VITAMIN D PRECURSORS
2688083	5/23/2008	Canada			PROCESS FOR PRODUCING PHOSPHINE OXIDE VITAMIN D PRECURSORS
200880018041.6	5/23/2008	China			PROCESS FOR PRODUCING PHOSPHINE OXIDE VITAMIN D PRECURSORS
08762721.2	5/23/2008	European Patent Office			PROCESS FOR PRODUCING PHOSPHINE OXIDE VITAMIN D PRECURSORS
7657/CHENP/2009	5/23/2008	India			PROCESS FOR PRODUCING PHOSPHINE OXIDE VITAMIN D PRECURSORS

Application No.	Filed	Country	Issued	Patent No.	Title
2010-509907	5/23/2008	Japan			PROCESS FOR
					PRODUCING PHOSPHINE
					OXIDE VITAMIN D
					PRECURSORS
IB08/01321	5/23/2008	PCT		**	PROCESS FOR
					PRODUCING PHOSPHINE
					OXIDE VITAMIN D
					PRECURSORS
12/128,992	5/29/2008	United States	10/18/2011	8,039,676	PROCESS FOR
		of America			PRODUCING PHOSPHINE
					OXIDE VITAMIN D
	1				PRECURSORS
61/036,021	3/12/2008	United States	~ 4		STABILIZED 1,25-
···· ,		of America			DIHYDROXYVITAMIN
					D2 AND METHOD OF
					MAKING SAME
2718238	3/12/2009	Canada			STABILIZED 1,25-
				]	DIHYDROXYVITAMIN
					D2 AND METHOD OF
					MAKING SAME
200980112429.7	3/12/2009	China			STABILIZED 1,25-
20090011212911				1	DIHYDROXYVITAMIN
					D2 AND METHOD OF
					MAKING SAME
09720292.3	3/12/2009	European			STABILIZED 1,25-
07720272.5		Patent Office			DIHYDROXYVITAMIN
					D2 AND METHOD OF
					MAKING SAME
11104112.2	3/12/2009	9 Hong Kong			STABILIZED 1,25-
1110111212					DIHYDROXYVITAMIN
					D2 AND METHOD OF
					MAKING SAME
2010-550007	3/12/2009	Japan			STABILIZED 1,25-
2010 00000				1	DIHYDROXYVITAMIN
					D2 AND METHOD OF
					MAKING SAME
CA09/00291	3/12/2009	PCT			STABILIZED 1,25-
0/10//00221	5,12,2005				DIHYDROXYVITAMIN
					D2 AND METHOD OF
		1			MAKING SAME
12/403,271	3/12/2009	United States			STABILIZED 1,25-
141753411	0.12/2007	of America			DIHYDROXYVITAMIN
					D2 AND METHOD OF
					MAKING SAME
61/175,919	5/6/2009	United States			FRET-BASED
011113,717	01010007	of America			BIOSENSOR TO
					QUANTIFY 25-
					HYDROXYVITAMIN D
10740698.5	5/3/2010	European			METHODS AND
10/40020.0	51512010	Patent Office			COMPOSITION FOR
					MEASURING THE
					AMOUNT OF VITAMIN D
					DERIVATIVES

Application No.	Filed	Country	Issued	Patent No.	Title
IB10/001123	5/3/2010	PCT			METHODS AND
		-			COMPOSITION FOR
					MEASURING THE
					AMOUNT OF VITAMIN D
					DERIVATIVES
13/318,442	12/21/2011	United States			METHODS AND
		of America			COMPOSITION FOR
					MEASURING THE
					AMOUNT OF VITAMIN D
					DERIVATIVES
61/118,030	11/26/2008	United States			METHOD FOR
		of America			SYNTHESIZING
					VITAMIN D ANALOGS
2744591	11/25/2009	Canada			METHOD FOR
2111091	1112012003	Curran .			SYNTHESIZING
					VITAMIN D ANALOGS
200980152913.2	11/25/2009	China			METHOD FOR
200900152915.2	11/2012000	China			SYNTHESIZING
					VITAMIN D ANALOGS
09828488.8	11/25/2009	European			METHOD FOR
09828488.8	11/25/2009	Patent Office			SYNTHESIZING
		Faterit Office		ł	VITAMIN D ANALOGS
1000/010000011	11/05/2000	India			METHOD FOR
4382/CHENP/2011	11/25/2009	India			SYNTHESIZING
					VITAMIN D ANALOGS
	11/0 # /0 000				METHOD FOR
2011-537801	11/25/2009	Japan			
					SYNTHESIZING
					VITAMIN D ANALOGS
CA09/01687	11/25/2009	PCT			METHOD FOR
			1		SYNTHESIZING
					VITAMIN D ANALOGS
13/131,176	7/19/2011	United States			METHOD FOR
		of America			SYNTHESIZING
					VITAMIN D ANALOGS
61/147,348	1/26/2009	United States			PHOSPHATE
		of America			MANAGEMENT WITH
					SMALL MOLECULES
2746832	1/26/2010	Canada			PHOSPHATE
					MANAGEMENT WITH
					SMALL MOLECULES
10733188.6	1/26/2010	European			PHOSPHATE
		Patent Office			MANAGEMENT WITH
					SMALL MOLECULES
12105315.3	1/26/2010	Hong Kong			PHOSPHATE
					MANAGEMENT WITH
					SMALL MOLECULES
2011-546558	1/26/2010	Japan			PHOSPHATE
2011 0 10000	1	<b>r</b>			MANAGEMENT WITH
	1				SMALL MOLECULES
CA10/00111	1/26/2010	РСТ			РНОЅРНАТЕ
CATWOVITI	1120/2010	101			MANAGEMENT WITH
	ł				SMALL MOLECULES

8

Application No.	Filed	Country	Issued	Patent No.	Title
13/146,217	10/19/2011	United States of America		~*	PHOSPHATE MANAGEMENT WITH SMALL MOLECULES

14116211.2

#### ASSIGNMENT AGREEMENT

This assignment agreement ("Assignment") is entered into the  $\partial \mathcal{P}^{th}$  day of <u>February</u>, 2013 ("Effective Date") by and between Cytochroma Inc., a company having a principal place of business at Ontario, Canada ("Assignor") and Cytochroma Cayman Islands Ltd., a company having a principal place of business at c/o Maples Corporate Services, PO Box 309 Ugland House, Grand Cayman, KY1-1104 Cayman Islands ("Assignee").

For good and valuable consideration, the receipt and sufficiency of which are agreed, Assignor hereby irrevocably sells, assigns and transfers to Assignee and its successors, assigns and legal representatives, Assignor's entire right, title and interest, both legal and equitable, throughout the world, in the patents and patent applications listed in the attached Exhibit A, and to the inventions described therein and improvements thereof, all related patent applications throughout the world including those claiming priority thereto anywhere in the world, the right of priority, including without limitation to claim priority benefit of or to said patent applications, all continuations, divisionals and continuations-in-part of any of the foregoing, patents issuing from any of the foregoing, and reissues, reexaminations, extensions and foreign equivalents thereof and supplementary protection certificates allowed on any of the foregoing (collectively the "Patent Rights") for Assignee's own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made; together with all income, royalties, damages or payments due or payable as of the Effective Date or thereafter, including, without limitation, all claims for damages by reason of past, present or future infringement or other unauthorized use of the Patent Rights, with the right to sue for, and collect the same for its own use and enjoyment, and for the use and enjoyment of its successors, assigns, or other legal representatives.

Upon the request of Assignee, the undersigned agrees to execute any and all documents and take actions reasonably requested to effectuate this Assignment and Assignee's rights in the Patent Rights, including any oath or affidavit relating thereto, to cooperate to the best of the ability of the undersigned with Assignee in preparing and executing statements and giving and producing evidence in support of the Patent Rights, and to perform any and all acts reasonably requested by Assignee to obtain, enforce and defend the Patent Rights and vest all rights therein to Assignee as fully and entirely as the same would have been held and enjoyed by the undersigned if this Assignment had not been executed.

The parties execute and deliver this Assignment by their respective signatories below.

The parties execute and deliver this Assignment by their respective signatories below.

Cytochroma Inc.

Per:

Name: Charles Bishop

Cytochroma Cayman Islands Ltd.

-------Per: \_\_\_\_

Name: Andrew Dean

Title: President and Chief Executive Officer

Date: \_\_\_\_\_, 2013

Witnesses:

Date: February 27, 2013

Witnesses:

2

Title: Director

1/10/

WENDY EDAMES

Cytochroma Inc.

Bu uli

Name: Charles Bishop

Title: President and Chief Executive Officer

Date: Februry 27, 2013

Witnesses:

Cytochroma Cayman Islands Ltd.

Name: Andrew Dean Title: Director

Date: \_\_\_\_\_, 2013

Witnesses:

## Exhibit A - Patents

Application No.	Filed	Country	Issued	Patent No.	Title
2488334	6/13/2003	Canada	12/7/2010	2488334	24-SULFOXIMINE
2400334					VITAMIN D3
					COMPOUNDS
3727105.3	6/13/2003	Switzerland	2/1/2012	1511725	24-SULFOXIMINE
\$727105.5	0/15/2005	01111111			VITAMIN D3
					COMPOUNDS
0000105.0	6/13/2003	Germany	2/1/2012	60339897.9	24-SULFOXIMINE
3727105.3	0/13/2003	Ochmany	LIUMOIT		VITAMIN D3
					COMPOUNDS
	6410,0000	European Patent	2/1/2012	1511725	24-SULFOXIMINE
03727105.3	6/13/2003		2/1/2012	10111120	VITAMIN D3
		Office			COMPOUNDS
			2/1/2012	1511725	24-SULFOXIMINE
3727105.3	6/13/2003	Spain	2/1/2012	1311723	VITAMIN D3
					COMPOUNDS
				1611006	24-SULFOXIMINE
3727105.3	6/13/2003	France	2/1/2012	1511725	VITAMIN D3
					COMPOUNDS
3727105.3	6/13/2003	6/13/2003 United Kingdom	2/1/2012	1511725	24-SULFOXIMINE
0.2.1.1.1.					VITAMIN D3
					COMPOUNDS
3727105.3	6/13/2003	/2003 Ireland	2/1/2012	1511725	24-SULFOXIMINE
5727105.5					VITAMIN D3
					COMPOUNDS
3727105.3	6/13/2003	Italy	2/1/2012	1511725	24-SULFOXIMINE
3727105.5					VITAMIN D3
					COMPOUNDS
	6/13/2003	Jonan	4/9/2010	4490262	24-SULFOXIMINE
2004513244	0/13/2003	Japan	4, 57 2010		VITAMIN D3
					COMPOUNDS
			2/1/2012	1511725	24-SULFOXIMINE
3727105.3	6/13/2003	Luxembourg	2/1/2012	1511125	VITAMIN D3
	1				COMPOUNDS
			0/1/2010	1511725	24-SULFOXIMINE
3727105.3	6/13/2003	Monaco	2/1/2012	1511725	VITAMIN D3
					COMPOUNDS
					24-SULFOXIMINE
CA03/00851	6/13/2003	PCT			VITAMIN D3
		1			
					COMPOUNDS
10/460,656	6/13/2003	United States of	9/5/2006	7,101,865	24-SULFOXIMINE
		America			VITAMIN D3
					COMPOUNDS
11/442,148	5/30/2006	United States of	7/5/2011	7,973,024	24-SULFOXIMINE
11/992,190	0,00,2000	America			VITAMIN D3
		1			COMPOUNDS
(0.000.004	6/13/2002	United States of		-+	24-SULFOXIMINE
60/387,904	0/15/2002	America	1		VITAMIN D3
		Atteriea			COMPOUNDS

Application No.	Filed	Country	Issued	Patent No.	Title
2458415	8/22/2002	Canada	9/21/2010	2458415	24-SULFUR-
					SUBSTITUTED
					ANALOGS OF 1ALPHA,
					25-DIHYDROXY
					VITAMIN D3
2752924.7	8/22/2002	Switzerland	4/15/2009	1419143	24-SULFUR-
					SUBSTITUTED
					ANALOGS OF IALPHA,
					25-DIHYDROXY
		1	1		VITAMIN D3
2752924.7	8/22/2002	Germany	4/15/2009	60231987.0	24-SULFUR-
					SUBSTITUTED
					ANALOGS OF 1ALPHA,
			1		25-DIHYDROXY
					VITAMIN D3
02752924.7	8/22/2002	European Patent	4/15/2009	1419143	24-SULFUR-
04172727.7	0/22/2002	Office			SUBSTITUTED
		- Children	1		ANALOGS OF 1ALPHA,
					25-DIHYDROXY
					VITAMIN D3
2752924.7	8/22/2002	France	4/15/2009	1419143	24-SULFUR-
2132324.1	0/22/2002	Tranco	1,10,2007	1115110	SUBSTITUTED
					ANALOGS OF 1ALPHA,
					25-DIHYDROXY
					VITAMIN D3
2752924.7	8/22/2002	United Kingdom	4/15/2009	1419143	24-SULFUR-
2132924.1	0/22/2002	United Kingdom	4,13,2009	1417145	SUBSTITUTED
					ANALOGS OF 1ALPHA,
					25-DIHYDROXY
					VITAMIN D3
2752924.7	8/22/2002	8/22/2002 Italy	4/15/2009	1419143	24-SULFUR-
2152924.7	0/22/2002	11017	1110/2007		SUBSTITUTED
					ANALOGS OF 1ALPHA,
					25-DIHYDROXY
					VITAMIN D3
2003523209	8/22/2002	Japan			24-SULFUR-
2003323209	0/22/2002	Jahan			SUBSTITUTED
					ANALOGS OF IALPHA,
					25-DIHYDROXY
			Ē		VITAMIN D3
CA02/01294	8/22/2002	PCT			24-SULFUR-
CA02/01294	0/22/2002	101			SUBSTITUTED
					ANALOGS OF IALPHA,
					25-DIHYDROXY
					VITAMIN D3
60/328,429	10/12/2001	United States of			24-ARYL SULFONE
00/328,429	10/12/2001	America	-	-	ANALOGS OF 1ALPHA,
		Amorica			25- DIHYDROXY
			1	1	VITAMIN D3
(0/202 021	6/12/2002	United States of			24-ARYL SULFONE
60/387,931	6/13/2002		-	1	ANALOGS OF IALPHA,
		America			25- DIHYDROXY
					VITAMIN D3
	l		l		

Application No.	Filed	Country	Issued	Patent No.	Title
10/225,475	8/22/2002	United States of America			24-SULFUR- SUBSTITUTED
					ANALOGS OF IALPHA, 25-DIHYDROXY VITAMIN D3
10/612,302	7/3/2003	United States of America	1/23/2007	7,166,585	24-SULFUR- SUBSTITUTED ANALOGS OF 1 ALPHA, 25-DIHYDROXY VITAMIN D3
2767010.8	10/11/2002	Austria	4/18/2007	1436257	LOW-CALCEMIC OXIME ANALOGS OF 1ALPHA, 25-DIHYDROXY VITAMIN D3
2767010.8	10/11/2002	Belgium	4/18/2007	1436257	LOW-CALCEMIC OXIME ANALOGS OF 1ALPHA, 25-DIHYDROXY VITAMIN D3
2463505	10/11/2002	Canada	7/12/2011	2463505	LOW-CALCEMIC OXIME ANALOGS OF 1ALPHA, 25-DIHYDROXY VITAMIN D3
2767010.8	10/11/2002	Switzerland	4/18/2007	1436257	LOW-CALCEMIC OXIME ANALOGS OF IALPHA, 25-DIHYDROXY VITAMIN D3
2767010.8	10/11/2002	Cyprus	4/18/2007	1436257	LOW-CALCEMIC OXIME ANALOGS OF 1ALPHA, 25-DIHYDROXY VITAMIN D3
2767010.8	10/11/2002	Germany	4/18/2007	60219655.8	LOW-CALCEMIC OXIME ANALOGS OF 1ALPHA, 25-DIHYDROXY VITAMIN D3
2767010.8	10/11/2002	Denmark	4/18/2007	1436257	LOW-CALCEMIC OXIME ANALOGS OF IALPHA, 25-DIHYDROXY VITAMIN D3
02767010.8	10/11/2002	European Patent Office	4/18/2007	1436257	LOW-CALCEMIC OXIME ANALOGS OF 1ALPHA, 25-DIHYDROXY VITAMIN D3
2767010.8	10/11/2002	Spain	4/18/2007	1436257	LOW-CALCEMIC OXIME ANALOGS OF 1ALPHA, 25-DIHYDROXY VITAMIN D3
2767010,8	10/11/2002	Finland	4/18/2007	1436257	LOW-CALCEMIC OXIME ANALOGS OF IALPHA, 25-DIHYDROXY VITAMIN D3
2767010.8	10/11/2002	France	4/18/2007	1436257	LOW-CALCEMIC OXIME ANALOGS OF 1ALPHA, 25-DIHYDROXY VITAMIN D3

and the second second

and the second second

- - -

5

Application No.	Filed	Country	Issued	Patent No.	Title LOW-CALCEMIC OXIME
2767010.8	10/11/2002	United Kingdom	4/18/2007	1436257	
2107010.0		-			ANALOGS OF 1ALPHA,
		:			25-DIHYDROXY
					VITAMIN D3
2767010.8	10/11/2002	Greece	4/18/2007	1436257	LOW-CALCEMIC OXIME
2101010.0	10/11/2002				ANALOGS OF 1ALPHA,
					25-DIHYDROXY
					VITAMIN D3
2767010.8	10/11/2002	Ireland	4/18/2007	1436257	LOW-CALCEMIC OXIME
2707010.0	10/11/2002				ANALOGS OF 1ALPHA,
			i.		25-DIHYDROXY
					VITAMIN D3
00(0010.0	10/11/2002	Italy	4/18/2007	1436257	LOW-CALCEMIC OXIME
2767010.8	10/11/2002	itary			ANALOGS OF 1ALPHA,
					25-DIHYDROXY
					VITAMIN D3
	10/11/2002	Japan	1/8/2010	4436674	LOW-CALCEMIC OXIME
2003-534384	10/11/2002	заран	110/2010		ANALOGS OF 1ALPHA,
					25-DIHYDROXY
					VITAMIN D3
	10/11/0000	Luxembourg	4/18/2007	1436257	LOW-CALCEMIC OXIME
2767010.8	10/11/2002	Luxembourg	4/10/2007	1 10 0 2 0 1	ANALOGS OF 1ALPHA,
					25-DIHYDROXY
		1			VITAMIN D3
			4/18/2007	1436257	LOW-CALCEMIC OXIME
2767010.8	10/11/2002	Monaco	4/16/2007	1450257	ANALOGS OF 1ALPHA,
					25-DIHYDROXY
					VITAMIN D3
			4/18/2007	1436257	LOW-CALCEMIC OXIME
2767010.8	10/11/2002	Netherlands	4/18/2007	1450257	ANALOGS OF IALPHA,
					25-DIHYDROXY
					VITAMIN D3
					LOW-CALCEMIC OXIME
CA02/01519	10/11/2002	PCT			ANALOGS OF 1ALPHA,
					25-DIHYDROXY
					VITAMIN D3
				1 10 (0 (7	LOW-CALCEMIC OXIME
2767010.8	10/11/2002	Portugal	4/18/2007	1436257	ANALOGS OF 1ALPHA,
					25-DIHYDROXY
					VITAMIN D3
					LOW-CALCEMIC OXIME
2767010.8	10/11/2002	Sweden	4/18/2007	1436257	ANALOGS OF IALPHA,
270101010					
					25-DIHYDROXY
	4				VITAMIN D3
10/270,158	10/15/2002	United States of	1/3/2006	6,982,258	LOW-CALCEMIC OXIME
10/2/0,100		America	1		ANALOGS OF IALPHA,
					25-DIHYDROXY
					VITAMIN D3
(0/200 100	10/12/2001	United States of			LOW-CALCEMIC OXIMI
60/328,428	10/12/2001	America			ANALOGS OF 1ALPHA,
		1			25-DIHYDROXY
		1	1		VITAMIN D3

.\_\_\_\_.

and the second .....

۰.

Application No.	Filed	Country	Issued	Patent No.	Title
2510228	12/18/2003	Canada	10/30/2012	2510228	25-SO2-SUBSTITUTED ANALOGS OF IALPHA, 25- DIHYDROXYVITAMIN D3
CA03/01926	12/18/2003	РСТ			25-SO2-SUBSTITUTED ANALOGS OF IALPHA, 25- DIHYDROXYVITAMIN D3 (CALCITRIOL)
10/738,248	12/18/2003	United States of America	1/31/2012	8,106,035	25-S02-SUBSTITUTED ANALOGS OF 1a,25- DIHYDROXYVITAMIN D3
60/674,282	4/25/2005	United States of America			LOW-CALCEMIC 16, 23- DIENE 25-OXIME ANALOGS OF 1ALPHA,25- DIHYDROXY VITAMIN D3
2605815	4/25/2006	Canada			LOW-CALCEMIC 16,23- DIENE 25-OXIME ANALOGS OF 1ALPHA,25- DIHYDROXY VITAMIN D3
06721850.3	4/25/2006	European Patent Office			LOW-CALCEMIC 16,23- DIENE 25-OXIME ANALOGS OF 1ALPHA,25- DIHYDROXY VITAMIN D3
2008-508035	4/25/2006	Japan			LOW-CALCEMIC 16,23- DIENE 25-OXIME ANALOGS OF IALPHA,25- DIHYDROXY VITAMIN D3
CA06/00657	4/25/2006	PCT			LOW-CALCEMIC 16,23- DIENE 25-OXIME ANALOGS OF 1 ALPHA,25- DIHYDROXY VITAMIN D3
11/912,395	11/11/2008	United States of America			Low Calcemic 16, 23 Diene 25-Oxime Analogs of 1alpha, 25 Dihydroxy Vitamin D3
61/294,741	1/13/2010	United States of America			1-DEOXY ANALOGS OF 1,25- DIHYDROXYVITAMIN D3 COMPOUNDS

Application No.	Filed	Country	Issued	Patent No.	Title
2012-549078	1/13/2011	Japan			1-DEOXY ANALOGS OF VITAMIN D-RELATED COMPOUNDS
PCT/US11/21129	1/13/2011	PCT			I-DEOXY ANALOGS OF 1,25- DIHYDROXYVITAMIN D3 COMPOUNDS
13/521,980	7/12/2012	United States of America			1-DEOXY ANALOGS OF 1,25- DIHYDROXYVITAMIN D3 COMPOUNDS

14116185.2

#### ASSIGNMENT AGREEMENT

This assignment agreement ("Assignment") is entered into the  $27^{th}$  day of February 2013 ("Effective Date") by and between Cytochroma Inc., a company having a principal place of business at Ontario, Canada ("Assignor") and Cytochroma Cayman Islands Ltd., a company having a principal place of business at c/o Maples Corporate Services, PO Box 309 Ugland House, Grand Cayman, KY1-1104 Cayman Islands ("Assignee").

For good and valuable consideration, the receipt and sufficiency of which are agreed, Assignor hereby irrevocably sells, assigns and transfers to Assignee and its successors, assigns and legal representatives, Assignor's entire right, title and interest, both legal and equitable, throughout the world, in the patents and patent applications listed in the attached Exhibit A, and to the inventions described therein and improvements thereof, all related patent applications throughout the world including those claiming priority thereto anywhere in the world, the right of priority, including without limitation to claim priority benefit of or to said patent applications, all continuations, divisionals and continuations-in-part of any of the foregoing, patents issuing from any of the foregoing, and reissues, reexaminations, extensions and foreign equivalents thereof and supplementary protection certificates allowed on any of the foregoing (collectively the "Patent Rights") for Assignee's own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made; together with all income, royalties, damages or payments due or payable as of the Effective Date or thereafter, including, without limitation, all claims for damages by reason of past, present or future infringement or other unauthorized use of the Patent Rights, with the right to sue for, and collect the same for its own use and enjoyment, and for the use and enjoyment of its successors, assigns, or other legal representatives.

Upon the request of Assignee, the undersigned agrees to execute any and all documents and take actions reasonably requested to effectuate this Assignment and Assignee's rights in the Patent Rights, including any oath or affidavit relating thereto, to cooperate to the best of the ability of the undersigned with Assignee in preparing and executing statements and giving and producing evidence in support of the Patent Rights, and to perform any and all acts reasonably requested by Assignee to obtain, enforce and defend the Patent Rights and vest all rights therein to Assignee as fully and entirely as the same would have been held and enjoyed by the undersigned if this Assignment had not been executed.

The parties execute and deliver this Assignment by their respective signatories below.

Cytochroma Cayman Islands Ltd. Cytochroma Inc. 2 Name: Andrew Dean Name: Charles Bishop Title: Director Title: President and Chief Executive Officer Date: February 27, 2013 Date: \_\_\_\_\_, 2013 Witnesses: Witnesses: VENDY ESNE Approved and consented to this \_\_\_\_\_ day of \_\_\_\_\_, 2013 Proventiv Therapeutics, LLC Name: Charles Bishop

Title: President and Chief Executive Officer

Cytochroma Inc.

lui Bisto

Name: Charles Bishop Title: President and Chief Executive Officer Date: <u>February</u>  $2\overline{2}$ , 2013

Witnesses:

Cytochroma Cayman Islands Ltd.

Name: Andrew Dean Title: Director Date: \_\_\_\_\_, 2013

Witnesses:

Approved and consented to this  $27^{+4}$  day of <u>February</u>, 2013

Proventiv Therapeutics, LLC

Culic Bosq

Name: Charles Bishop

Title: President and Chief Executive Officer

Exhibit A - Patents

Application No.	Filed	Country	Issued	Patent No.	Title
60/913,848	4/25/2007	United States of America			METHODS AND COMPOUNDS FOR VITAMIN D THERAPY
2684778	4/25/2008	Canada			METHODS AND COMPOUNDS FOR VITAMIN D THERAPY
08746915.1	4/25/2008	European Patent Office			METHODS AND COMPOUNDS FOR VITAMIN D THERAPY
2010-50652	4/25/2008	Japan	** 8		METHODS AND COMPOUNDS FOR VITAMIN D THERAPY
US08/61586	4/25/2008	РСТ			METHODS AND COMPOUNDS FOR VITAMIN D THERAPY
12/597,224	4/16/2010	United States of America			METHODS AND COMPOUNDS FOR VITAMIN D THERAPY
60/913,853	4/25/2007	United States of America			Methods and Compositions for Controlled Release Oral Dosage of a Vitamin D Compound
2683997	4/25/2008	Canada			ORAL CONTROLLED RELEASE COMPOSITIONS COMPRISING VITAMIN D COMPOUND AND WAXY CARRIER
200880013357.6	4/25/2008	China			METHODS AND COMPOSITIONS FOR CONTROLLED RELEASE ORAL DOSAGE OF A VITAMIN D COMPOUND
08746908.6	4/25/2008	European Patent Office			METHODS AND COMPOSITIONS FOR CONTROLLED RELEASE ORAL DOSAGE OF A VITAMIN D COMPOUND
10108648.7	4/25/2008	Hong Kong			METHODS AND COMPOSITIONS FOR CONTROLLED RELEASE ORAL DOSAGE OF A VITAMIN D COMPOUND
2010-506520	4/25/2008	Japan			ORAL CONTROLLED RELEASE COMPOSITIONS COMPRISING VITAMIN D COMPOUND AND WAXY CARRIER
10-2009-7024328	4/25/2008	Korea, Republic of			ORAL CONTROLLED RELEASE COMPOSITIONS COMPRISING VITAMIN D COMPOUND AND WAXY CARRIER

Application No.	Filed	Country	Issued	Patent No.	Title
US08/61579	4/25/2008	PCT			METHODS AND COMPOSITIONS FOR
					CONTROLLED RELEASE
					ORAL DOSAGE OF A
				·	VITAMIN D COMPOUND
12/109,983	4/25/2008	United States			Methods and Compositions for
		of America			Controlled Release Oral Dosage
					of a Vitamin D Compound
12154573.5	4/25/2008	European		1	ORAL CONTROLLED
		Patent Office			RELEASE COMPOSITIONS
					COMPRISING VITAMIN D COMPOUND AND WAXY
				0.007.1.10	CARRIER METHOD FOR TREATING
13/244,945	9/26/2011	United States	6/26/2012	8,207,149	SECONDARY
		of America			HYPERPARATHYROIDISM
					IN CKD
		11.1.1.0.1	<u> </u>		METHODS FOR
13/746,982	1/22/2013	United States			CONTROLLED RELEASE
		of America			ORAL DOSAGE OF A
				:	VITAMIN D COMPOUND
<u> </u>	C/01/0007	I Inite J Ctaton			METHOD OF TREATING
60/815,148	6/21/2006	United States of America			AND PREVENTING
		of America			SECONDARY
					HYPOTHYROIDISM
0.665400	6/21/2007	Canada			METHOD OF TREATING
2655499	0/21/2007	Canada			AND PREVENTING
				1	SECONDARY
					HYPERPARATHYROIDISM
07840277.3	6/21/2007	European			METHOD OF TREATING
0/840277.5	0/21/2007	Patent Office			AND PREVENTING
		Future office	]		SECONDARY
					HYPERPARATHYROIDISM
2009-516725	6/21/2007	Japan			METHOD OF TREATING
2007-010725	0/21/2007	, when			AND PREVENTING
					SECONDARY
					HYPERPARATHYROIDISM
US07/71791	6/21/2007	PCT			METHOD OF TREATING
000///////	0,21,2001				AND PREVENTING SHPT IN
					THE EARLY STAGES OF
			1		CKD
12/305,572	3/2/2009	United States	12/11/2012	8,329,677	METHOD OF TREATING
		of America			AND PREVENTING
				1	SECONDARY
					HYPERPARATHYROIDISM
13/680,997	11/19/2012	United States			METHOD OF TREATING
		of America			AND PREVENTING
					SECONDARY
			1		HYPERPARATHYROIDISM

------

4

PATENT REEL: 037460 FRAME: 0861

•

. . . .

.

Application No.	Filed	Country	Issued	Patent No.	Title
61/041,898	4/2/2008	United States of America			METHODS OF DIAGNOSING VITAMIN D DEFICIENCY, SUSCEPTIBILITY THERETO, TREATMENT THEREOF, AND PREVENTION THEREOF
61/161,292	3/18/2009	United States of America			Methods of Diagnosing Vitamin D Deficiency, Susceptibility Thereto, Treatment Thereof, and Prevention Thereof
2714996	4/2/2009	Canada			METHODS, COMPOSITIONS, USES, AND KITS USEFUL FOR VITAMIN D DEFICIENCY AND RELATED DISORDERS
200980120404.1	4/2/2009	China			METHODS, COMPOSITIONS, USES, AND KITS USEFUL FOR VITAMIN D DEFICIENCY AND RELATED DISORDERS
09729007.6	4/2/2009	European Patent Office	- 4		METHODS, COMPOSITIONS, USES, AND KITS USEFUL FOR VITAMIN D DEFICIENCY AND RELATED DISORDERS
11111063.6	4/2/2009	Hong Kong			METHODS, COMPOSITIONS, USES, AND KITS USEFUL FOR VITAMIN D DEFICIENCY AND RELATED DISORDERS
10-2010-7024664	4/2/2009	Korea, Republic of			METHODS, COMPOSITIONS, USES, AND KITS USEFUL FOR VITAMIN D DEFICIENCY AND RELATED DISORDERS
US09/39355	4/2/2009	РСТ			METHODS OF DIAGNOSING VITAMIN D DEFICIENCY, SUSCEPTIBILITY THERETO, TREATMENT THEREOF, AND PREVENTION
12/935,139	11/12/2010	United States of America			METHODS COMPOSITIONS, USES, AND KITS USEFUL FOR VITAMIN D DEFICIENCY AND RELATED DISORDERS
61/318,741	3/29/2010	United States of America			Methods and Compositions for Administration of a Vitamin D Compound
61/405,196	10/20/2010	United States of America			METHODS AND COMPOSITIONS FOR CONTROLLED RELEASE ORAL DOSAGE OF A 25- HYDROXYVITAMIN D COMPOUND

- - -

5

Application No.	Filed	Country	Issued	Patent No.	Title
2797537	3/29/2011	Canada			METHODS AND COMPOSITIONS FOR REDUCING PARATHYROID LEVELS
201180024227.4	3/29/2011	China			METHODS AND COMPOSITIONS FOR REDUCING PARATHYROID LEVELS
11763340.4	3/29/2011	European Patent Office			METHODS AND COMPOSITIONS FOR REDUCING PARATHYROID LEVELS
10-2012-7028117	3/29/2011	Korea, Republic of			METHODS AND COMPOSITIONS FOR REDUCING PARATHYROID LEVELS
PCT/US11/30404	3/29/2011	РСТ			METHODS AND COMPOSITIONS FOR REDUCING PARATHYROID LEVELS
13/638,845	10/1/2012	United States of America			METHODS AND COMPOSITIONS FOR REDUCING PARATHYROID LEVELS

14116203.2

. . . .